Invivyd (IVVD) Projected to Announce Earnings on Thursday

Key Points

• Invivyd is expected to report Q3 2026 results before market open on November 5, 2026. Analysts forecast a loss of $0.11 per share and revenue of approximately $15.04 million.
• The company’s previous quarter fell short of expectations, reporting a $0.14-per-share loss versus the $0.11 consensus estimate and revenue of $14.29 million versus $14.40 million expected.
• Invivyd shares recently traded near $0.62, close to their one-year low of $0.53. Analyst sentiment is mixed, with an average rating of “Hold” and a consensus price target of $10.00.

Invivyd (NASDAQ:IVVD - Get Free Report) is anticipated to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Invivyd to post earnings of ($0.11) per share and revenue of $15.04 million for the quarter. Investors can check the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Invivyd (NASDAQ:IVVD - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. The firm had revenue of $14.29 million during the quarter, compared to analyst estimates of $14.40 million. On average, analysts expect Invivyd to post ($0.51) EPS for the current fiscal year and ($0.43) EPS for the next fiscal year.

Invivyd Stock Performance

Shares of NASDAQ IVVD opened at $0.62 on Thursday. The company's fifty day moving average price is $0.80 and its 200 day moving average price is $1.19. Invivyd has a 1 year low of $0.53 and a 1 year high of $3.07. The company has a market capitalization of $181.75 million, a PE ratio of -1.87 and a beta of 0.95.

Analyst Ratings Changes

IVVD has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating on shares of Invivyd in a report on Tuesday, September 29th. BTIG Research reiterated a "buy" rating on shares of Invivyd in a research report on Monday, September 14th. Weiss Ratings raised shares of Invivyd from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, September 8th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Invivyd in a research report on Thursday, August 27th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Invivyd currently has an average rating of "Hold" and a consensus price target of $10.00.

Insider Activity

In related news, insider Jill Andersen sold 37,256 shares of Invivyd stock in a transaction on Monday, August 17th. The shares were sold at an average price of $0.72, for a total value of $26,824.32. Following the sale, the insider owned 314,480 shares of the company's stock, valued at approximately $226,425.60. This trade represents a 10.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 228,024 shares of company stock worth $176,540. Company insiders own 12.25% of the company's stock.

About Invivyd

Invivyd, Inc is a biotechnology company focused on developing antibody-based medicines designed to prevent and treat infectious diseases. The company uses its antibody discovery and engineering technologies to create broadly neutralizing antibodies intended to remain effective as viruses evolve.

Invivyd's lead product is pemivibart, marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration granted pemivibart an Emergency Use Authorization in 2024 for pre-exposure prophylaxis against COVID-19 in certain individuals who are moderately or severely immunocompromised and unlikely to mount an adequate immune response to vaccination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.